Cargando…

Biomarkers for Predicting the Occurrence and Progression of Atrial Fibrillation: Soluble Suppression of Tumorigenicity 2 Protein and Tissue Inhibitor of Matrix Metalloproteinase-1

BACKGROUND: Soluble suppression of tumorigenicity 2 protein (sST2) and tissue inhibitor of matrix metalloproteinase (TIMP)-1 are involved in multiple pathogenic pathways, including cardiac remodeling, which is the main pathology of atrial fibrillation (AF). This study aims to investigate the previou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Wei-Ping, Du, Xiao, Chen, Jun-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825235/ https://www.ncbi.nlm.nih.gov/pubmed/36683600 http://dx.doi.org/10.1155/2022/6926510

Ejemplares similares

Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation
por: Tan, Ruopeng, et al.
Publicado: (2021)

Soluble suppression of tumorigenicity 2 associated with atrial fibrillation detected after stroke: A retrospective study
por: Hou, Wenquan, et al.
Publicado: (2023)

Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases Are Essential for the Inflammatory Response in Cancer Cells
por: Sun, Jun
Publicado: (2010)

Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Are Potential Biomarkers of Pulmonary and Extra-Pulmonary Tuberculosis
por: Kathamuthu, Gokul Raj, et al.
Publicado: (2020)

Membrane-type 1 matrix metalloproteinase-mediated progelatinase A activation in non-tumorigenic and tumorigenic humaneratinocytes
por: Baumann, P, et al.
Publicado: (2000)

Plasma Matrix Metalloproteinase-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 as Prognostic Biomarkers in Critically Ill Patients
por: Duda, Izabela, et al.
Publicado: (2020)

Matrix metalloproteinases and their inhibitors as biomarkers of severity in sepsis
por: Lorente, Leonardo, et al.
Publicado: (2010)

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in the hair cycle
por: HOU, CHUN, et al.
Publicado: (2016)

Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis
por: Yang, Hyun Suk, et al.
Publicado: (2016)

Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases Ratio: A Biomarker of Bone Resorption in Geriatric Osteoporosis?
por: Bektan Kanat, Bahar, et al.
Publicado: (2023)

Knockdown of N-Acetylglucosaminyltransferase-II Reduces Matrix Metalloproteinase 2 Activity and Suppresses Tumorigenicity in Neuroblastoma Cell Line
por: Hall, M. Kristen, et al.
Publicado: (2020)

Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis
por: Lorente, Leonardo, et al.
Publicado: (2009)

Plasma levels of the tissue inhibitor matrix metalloproteinase-3 as a potential biomarker in oral cancer progression
por: Su, Chun-Wen, et al.
Publicado: (2017)

Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer
por: Zhang, Yangyu, et al.
Publicado: (2020)

Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
por: Tanaka, Komei, et al.
Publicado: (2013)

Kinetochore-associated protein 1 promotes the invasion and tumorigenicity of cervical cancer cells via matrix metalloproteinase-2 and matrix metalloproteinase-9
por: Wang, Caimei, et al.
Publicado: (2022)

Impact of Midregional N‐Terminal Pro–Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treated With Catheter Ablation for Atrial Fibrillation: The Biorhythm Study
por: Badoz, Marc, et al.
Publicado: (2021)

Association of soluble suppression of tumorigenicity 2 protein with new-onset atrial fibrillation in patients with acute ST-segment elevation myocardial infarction undergoing primary PCI
por: Zhao, Ting-ting, et al.
Publicado: (2023)

Selected Metal Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases as Potential Biomarkers for Tubulointerstitial Fibrosis in Children with Unilateral Hydronephrosis
por: Bieniaś, Beata, et al.
Publicado: (2020)

Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal Muscles
por: Alameddine, Hala S., et al.
Publicado: (2016)

Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast Carcinomas
por: Iwata, Hiroji, et al.
Publicado: (1996)

Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Echinoderms: Structure and Possible Functions
por: Dolmatov, Igor Yu., et al.
Publicado: (2021)

Higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation
por: Li, Haiwei, et al.
Publicado: (2022)

Effects of reduced β(2)-glycoprotein I on the expression of aortic matrix metalloproteinases and tissue inhibitor matrix metalloproteinases in diabetic mice
por: Xu, Jun, et al.
Publicado: (2014)

Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?
por: Hoffmann, Ursula, et al.
Publicado: (2009)

Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
por: Huang, Dong-Hui, et al.
Publicado: (2016)

Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Prostate Cancer Progression
por: Gong, Yixuan, et al.
Publicado: (2014)

Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma
por: Qiao, Zhen-kui, et al.
Publicado: (2013)

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in murine β-coronavirus-induced neuroinflammation
por: Sengupta, Sourodip, et al.
Publicado: (2022)

Erratum: Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Matrix Metalloproteinase-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in Sepsis after Major Abdominal Surgery
por: Bojic, Suzana, et al.
Publicado: (2018)

Roles of osteopontin and matrix metalloproteinase-7 in occurrence, progression, and prognosis of nonsmall cell lung cancer
por: Sun, Ying, et al.
Publicado: (2015)

Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect
por: Pratama, Reza S., et al.
Publicado: (2020)

The serum matrix metalloproteinase-9 level is an independent predictor of recurrence after ablation of persistent atrial fibrillation
por: Wu, Gang, et al.
Publicado: (2016)

Elevated tissue inhibitor of metalloproteinase-1 along with left atrium hypertrophy predict atrial fibrillation recurrence after catheter ablation
por: Sun, Weiping, et al.
Publicado: (2022)

Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure
por: Öncel, Can Ramazan
Publicado: (2018)

Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
por: Iannazzo, Francesco, et al.
Publicado: (2022)

Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer
por: Zhang, Y., et al.
Publicado: (2017)

Renoprotective Action of a Matrix Metalloproteinase Inhibitor in Progressive Mesangioproliferative Nephritis
por: Kuroda, Takayuki, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j4qvojoe0e9u1f7upn44vn533t